Immunicum's patent application regarding the Company's core-technology for therapeutic cancer vaccination using allogeneic dendritic cells is being approved in the U.S.

Gothenburg, Sweden, 2013-10-25 08:53 CEST (GLOBE NEWSWIRE) — The United States Patent and Trademark Office (USPTO), has issued a notice of allowance regarding patent application 11/603,819 and thus intends to approve Immunicum’s patent application to protect the Company’s core-technology in the U.S. market.  

– The granted patent gives us significant protection for our core-technology also in the U.S. market. Along with the already granted European patent, we hereby have protection on the two most important markets for our products. Since we intend to eventually out-license our cancer vaccines, this is obviously of great importance to us, says Jamal El-Mosleh, CEO of Immunicum.

Immunicum’s vaccine cells are comprised of so-called allogeneic dendritic cells, which through a unique processing system are developed into effective immune activating cells. Immunicum’s unique vaccine concept is based on over 30 years of research in the field of transplantation immunology and, by use of a new method, activates the body’s own immune system to attack tumor cells. Immunicum’s shares have been traded since April 22, 2013 on NASDAQ OMX First North under the ticker IMMU.

G&W Fondkommission is chosen as the Company’s Certified Adviser.

Tel: +468-503 000 50.

For further information please contact:

Jamal El-Mosleh, CEO of Immunicum, +4631-772 81 50,

About Immunicum AB (publ):

Immunicum AB (publ) develops cancer immunotherapies. Its two main groups of therapeutic cancer vaccines, SUBCUVAX® and INTUVAX®, and the method of expansion of tumor-specific T-cells (CD70) is based on the Nobel prize awarded discovery of the dendritic cell and its central role in the activation of the specific immune response. Since the raw material consists of allogeneic dendritic cells, Immunicum’s products can be produced in large scale. The vaccines have proven efficacy in animal studies and are now undergoing clinical trials in renal cell carcinoma and hepatocellular carcinoma.

Keep reading

Immunicum doses the first patient in a new clinical phase I/II-study in primary liver cancer